Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.58% | -25.88% | 35.94% | -55.13% | -25.90% |
| Total Depreciation and Amortization | 32.28% | -2.33% | 10.24% | -0.27% | -10.04% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 170.54% | 129.44% | -73.20% | -151.44% | -165.07% |
| Change in Net Operating Assets | -89.69% | -1,769.84% | -392.92% | 117.63% | 232.52% |
| Cash from Operations | -0.13% | -71.41% | -80.53% | -34.01% | -34.69% |
| Capital Expenditure | 10.32% | -340.63% | -71.43% | 16.05% | 30.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 11.34% | -340.63% | 380.95% | 16.05% | -100.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -22,906.50% | -128,454.29% | -3.37% | 50.25% |
| Issuance of Common Stock | 120,550.57% | -100.00% | -100.00% | 9,974.11% | -97.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 528,751.67% | -128.25% | -198.01% | 11,798.15% | -99.44% |
| Foreign Exchange rate Adjustments | -262.17% | 192.84% | -317.86% | -1,121.73% | 193.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 568.04% | -244.51% | -2,643.20% | 482.08% | -141.95% |
